Biocon's Syngene in silent period but lays plans for API plant in India

By Dan Stanton

- Last updated on GMT

Syngene is buying 40 acres of land in Mangalore SEZ, India
Syngene is buying 40 acres of land in Mangalore SEZ, India

Related tags Special economic zone

Biocon subsidiary Syngene says it intends to build a commercial manufacturing plant for APIs and intermediates in Mangalore, India.

Syngene International is a subsidiary of drugmaker Biocon and offers contract development and manufacturing services to both customers in its home country India, and international biopharma firms.

In a filing with the Bombay Stock Exchange (BSE), the firm announced it is “in the process of acquiring approximately 40 acres of land on leasehold basis in the multi-product Special Economic Zone [SEZ],” ​with the intention of “setting up commercial scale facilities for manufacture of novel Active Pharmaceutical Ingredients (APIs), Advanced Intermediates and Agro Chemicals for Syngene’s clients.”

As well as small molecule APIs, the CDMO produces biologics for its clients and is one of just a handful of Indian drugmakers​ which produce such products for Western biopharma companies. The firm also offers development services and last year announced a five-year extension of its collaboration with Bristol-Myers Squibb​.

The planned facility is located in Mangalore, Karnataka on the West coast of India. The announcement comes on the back of Biocon plans to build a biomanufacturing facility​ on the opposite side of India, at Pharma-City SEZ in Vizag, Andhra Pradesh.

SEZs offer businesses a number of incentives. The Mangalore site offers exemptions from industrial licensing norms including excise duty, purchase, service and sales tax.

IPO plans

This publication contacted parent company Biocon for more information, but spokesperson Seema Ahuja said the firm is in a silent period and cannot offer additional information.

Biocon is looking to list Syngene – India’s largest and Asia’s second-largest research services company – by the end of fiscal year 2015 and said in January it was hoping to sell up to 15% of its stake in the firm through an IPO.

In related news, Syngene’s Director, Peter Bains, has been appointed CEO of the subsidiary.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more